Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Doubling Down On Cardiac Regeneration, AstraZeneca Forms Research Alliance With Shanghai SIBS

This article was originally published in PharmAsia News

Executive Summary

Going deeper into the cardiac regeneration space, AstraZeneca signed an agreement with SIBS to research coronary artery regeneration.

You may also be interested in...



AZ Builds Cardiac Regeneration, Diabetes R&D At Swedish Research Hub

Diabetic nephropathy, pancreatic islet cell health as well as heart failure will feature in early-stage research conducted by AstraZeneca's cardiometabolic iMED based in Mölndal, Sweden - now one of three strategic R&D centers for the trimmed-down British drug maker.

AstraZeneca Bets Big On Moderna’s Preclinical Messenger RNA Technology

The struggling pharma pays $240 million upfront for an exclusive collaboration to discover, develop and commercialize mRNA drugs in the cardiovascular, metabolic, renal and oncology spaces.

AstraZeneca’s R&D Restructuring Follows Hot Spot Trend

In its most ambitious overhaul since the reorganization into iMeds in 2010, AstraZeneca’s latest R&D restructuring takes on three basic challenges: accessing innovation, improving internal productivity and reducing complexity and cost. It is the opening salvo in the new CEO’s vision for the troubled pharma.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1122620

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel